Maverick Capital Ltd. Has $1.18 Million Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Maverick Capital Ltd. grew its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 302.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,536 shares of the specialty pharmaceutical company's stock after purchasing an additional 13,926 shares during the period. Maverick Capital Ltd. owned about 0.09% of ANI Pharmaceuticals worth $1,180,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in ANIP. Innealta Capital LLC bought a new position in ANI Pharmaceuticals during the second quarter valued at approximately $65,000. Ridgewood Investments LLC bought a new stake in ANI Pharmaceuticals in the second quarter worth $85,000. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals during the first quarter worth $106,000. ADAR1 Capital Management LLC bought a new position in ANI Pharmaceuticals during the fourth quarter valued at about $132,000. Finally, Clear Street Markets LLC acquired a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth about $140,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock traded up $0.48 during trading hours on Friday, reaching $58.78. 184,636 shares of the company's stock were exchanged, compared to its average volume of 214,490. ANI Pharmaceuticals, Inc. has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $1.23 billion, a P/E ratio of 36.74 and a beta of 0.71. The business has a fifty day moving average price of $60.64 and a 200-day moving average price of $63.42.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.95 by $0.07. The firm had revenue of $138.00 million during the quarter, compared to analysts' expectations of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. During the same period in the prior year, the company earned $1.06 EPS. The business's quarterly revenue was up 18.5% compared to the same quarter last year. Analysts predict that ANI Pharmaceuticals, Inc. will post 3.58 EPS for the current fiscal year.

Analyst Ratings Changes

ANIP has been the topic of a number of analyst reports. Truist Financial reissued a "hold" rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. StockNews.com downgraded ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Raymond James lifted their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research report on Wednesday, September 18th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $78.80.

Insider Buying and Selling

In related news, COO Muthusamy Shanmugam sold 14,257 shares of the company's stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total value of $900,472.12. Following the completion of the transaction, the chief operating officer now directly owns 635,363 shares in the company, valued at $40,129,527.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Muthusamy Shanmugam sold 14,257 shares of the firm's stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total transaction of $900,472.12. Following the completion of the transaction, the chief operating officer now directly owns 635,363 shares of the company's stock, valued at approximately $40,129,527.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Chad Gassert sold 20,000 shares of the company's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the sale, the senior vice president now directly owns 193,226 shares in the company, valued at approximately $12,258,257.44. The disclosure for this sale can be found here. Insiders have sold a total of 46,007 shares of company stock valued at $2,911,790 over the last three months. 12.70% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.